Skip to main content
SAMJIN PHARMACEUTICAL CO.,LTD logo

SAMJIN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 005500 ISIN · KR7005500004 KO Manufacturing
Open in API
Filings indexed 253 across all filing types
Latest filing 2019-03-22 Declaration of Voting R…
Country KR South Korea
Listing KO 005500

About SAMJIN PHARMACEUTICAL CO.,LTD

https://www.samjinpharm.co.kr/

Samjin Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of medicines. The company's portfolio includes a wide range of over-the-counter (OTC) and prescription drugs, offered in various formulations such as oral, drop, and injectable forms. Notable products include the analgesic Gevorin, the antiplatelet agent Plavix, and the hypercholesterolemia treatment Newstatin-R. A central part of its strategy is a strong commitment to R&D, focusing on creating innovative new drugs to address diseases with high unmet medical needs. The company actively develops novel therapeutics for severe conditions, including cardiovascular, respiratory, and gastrointestinal diseases, with the goal of becoming a global pharmaceutical innovator.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the resolutions passed during the meeting, including financial statement reporting, dividend approval, director appointments, and other agenda items. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA), as it reports the official outcomes of shareholder votes at the AGM.
2019-03-22 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). This document specifically details changes to the company's board of directors, which falls under the category of Board/Management Information.
2019-03-22 Korean
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 100% confidence The document is an official announcement regarding the change of Representative Directors (CEO/Executive Officers) at Samjin Pharmaceutical. It lists the names of the directors before and after the change, the reason for the change (General Meeting of Shareholders and Board resolution), and the effective date. This falls directly under the definition of Board/Management Information (MANG).
2019-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal notification of the submission of an audit report ('감사보고서 제출') by Samjin Pharmaceutical. It provides key financial data, the auditor's opinion ('적정'), and the date of receipt. Since it is a short regulatory filing announcing the submission of the audit report rather than the full audit report document itself, it falls under the category of a report publication announcement. FY 2018
2019-03-14 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a listed company crosses certain thresholds. This specific document details the change in shareholding by Aviva Investors in Samjin Pharmaceutical Co., Ltd. In the provided classification schema, this type of major shareholding notification is categorized as 'Major Shareholding Notification' (MRQ).
2019-03-08 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Samjin Pharmaceutical Co., Ltd. It contains the meeting agenda, details on director candidates, financial statements (balance sheet, income statement, etc.), and management's discussion of business performance. While it contains financial data, it is specifically a proxy statement/notice for an upcoming shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2019-03-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.